ARTICLE | Company News
Vertex nears Orkambi reimbursement agreement with Australia
August 17, 2018 6:59 PM UTC
Australia's Pharmaceutical Benefits Advisory Committee (PBAC) recommended in July that the government subsidize the price of Orkambi lumacaftor/ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). The drug is approved to treat cystic fibrosis in patients ages six and older who have two copies of the F508del mutation.
The committee recommended Orkambi be listed on the country's Pharmaceutical Benefits Scheme (PBS) schedule under a Managed Access Program, which requires Vertex to provide long-term data showing the drug's benefits are sustained for at least four years...
BCIQ Company Profiles
BCIQ Target Profiles